Four-Drug 'Smart Stop' aims to halt tough lymphoma before chemo
NCT ID NCT04978584
Summary
This study is testing a new four-drug combination (rituximab, lenalidomide, acalabrutinib, tafasitamab) given before and alongside standard chemotherapy for adults newly diagnosed with a hard-to-treat type of aggressive lymphoma (non-germinal center DLBCL). The goal is to see if this approach helps control the cancer better. About 62 people will participate to measure how well the cancer responds and how safe the treatment is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.